FOLR1 and peritoneum cancer: Additionally, the phase III randomized GLORIOSA trial (NCT05445778) is comparing maintenance therapy with MIRV plus bevacizumab versus bevacizumab monotherapy in patients with FRα‐positive, platinum‐sensitive, high‐grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancers.